Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

WeedMD to supply cannabidiol for new research looking at liver disease treatments

Medical cannabis supplier WeedMD will supply Revive with CBD for the research program
WeedMD to supply cannabidiol for new research looking at liver disease treatments
Non-alcoholic steatohepatitis is the most extreme form of non-alcoholic fatty liver disease

Medical cannabis  producer  WeedMD Inc (CVE:WMD)  has struck a new research tie-up with Revive Therapeutics Ltd (CVE:RVV) looking at ways to treat liver disease using cannabidiol (CBD).

The former will supply Revive with CBD for the research program, specifically looking at non-alcoholic steatohepatitis (NASH) and autoimmune hepatitis (AIH).

Non-alcoholic steatohepatitis is the most extreme form of non-alcoholic fatty liver disease, while AIH is where the person's own immune system attacks the cells of the liver.

In addition, the two companies will identify opportunities for developing and commercializing medical cannabis products and therapies for potential collaborations on other treatments.

Revive recently secured the intellectual property (IP) for its own delivery systems, and has assembled a diversified pipeline of pharmaceutical, prescription and over-the-counter (OTC) products.

Together with WeedMD, it will evaluate the efficacy of CBD in the treatment of NASH and AIH, in addition to other potential indications in the future.

"WeedMD continues to push ahead with its research and development initiatives, both independently and with research institutions to accelerate cannabinoid applications and delivery system innovations, in addition to collecting valuable data about strains and their effects," said Dr Luc Duchesne, chief scientific officer at WeedMD.

"Both WeedMD and Revive are making advances as participants in the pharmaceutical cannabis market which begins with the validation of new products and innovations through clinical-evidence and the establishment of intellectual property.”

It's been a busy week for the pot-focused group.

On Monday, shares advanced as it received the green light to start growing in the first four grow rooms at its new greenhouse in Ontario.

The cultivation licence comes from Health Canada and is for 220,000 sq ft of retro-fitted tempered glass which is less than two years old.

It means the firm can now bring a total of 20 grow rooms on-line over the coming months.

View full WMD profile View Profile

WeedMD Timeline

Related Articles

1519327525_WeedMD-photo-for-Proactive.jpg
February 22 2018
The company is developing its medical cannabis for both domestic and global markets
Canntab pills
June 01 2018
The company is putting a pharmaceutical spin on the growing cannabis market

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use